SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Modeling how pre-existing TCR clones affect vaccine-induced T-cell responses

The project aims to develop a computational tool to predict vaccine-induced immune responses by analyzing T-cell receptor repertoires before and after vaccination.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

T-cells are increasingly recognized to be pivotal actors in the development of vaccine-induced immune responses. Through their T-cell receptor (TCR) on their cell surface, T-cells can recognize antigens derived from pathogens or vaccines. The strength of the interaction between the TCRs and the vaccine antigens will direct the T-cell dynamics after vaccination.

Project Overview

In this project, we will analyze the TCR repertoires from participants from three distinct vaccination cohorts prior to vaccination and after vaccination.

Computational Tool Development

We will develop a computational tool (later to be transformed into a software package) that will allow us to accurately predict, by using the baseline TCR data alone, which vaccinees will develop a robust immune response after vaccination.

Potential Impact

This tool holds the potential to have an important impact on different aspects and actors of vaccinology, ranging from the vaccine industry to public health researchers.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-12-2023
Einddatum31-5-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITEIT ANTWERPENpenvoerder

Land(en)

Belgium

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Computational scanning for responding clonotypes in immune repertoires

RESPOND is a user-friendly platform that integrates various algorithms to efficiently identify immune clonotypes for targeted vaccine and therapeutic development, reducing costs and time in drug discovery.

ERC Proof of...€ 150.000
2025
Details

Polyclonal anti-tumor immunity by engineered human T cells

This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.

ERC Starting...€ 1.812.500
2022
Details

Diagnostic model and assay for personalized vaccine

This project aims to develop a diagnostic assay to predict influenza vaccine responsiveness in immunocompromised patients using identified biomarkers and machine learning models, enhancing personalized vaccination strategies.

ERC Proof of...€ 150.000
2025
Details

Molecular mimicry as a key parameter shaping T cell immunity

The MIMIC project aims to explore molecular mimicry's role in T cell recognition to enhance cancer immunotherapy by optimizing antigen selection based on pre-existing immunity insights.

ERC Consolid...€ 2.000.000
2022
Details

Activation and switch of fates in T lymphocytes.

This project aims to model the fate choices of naïve and memory CD8+ T cells using experimental immunology and systems biology to enhance vaccine design and improve responses to infections and cancer.

ERC Consolid...€ 2.625.000
2025
Details
ERC Proof of...

Computational scanning for responding clonotypes in immune repertoires

RESPOND is a user-friendly platform that integrates various algorithms to efficiently identify immune clonotypes for targeted vaccine and therapeutic development, reducing costs and time in drug discovery.

ERC Proof of Concept
€ 150.000
2025
Details
ERC Starting...

Polyclonal anti-tumor immunity by engineered human T cells

This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.

ERC Starting Grant
€ 1.812.500
2022
Details
ERC Proof of...

Diagnostic model and assay for personalized vaccine

This project aims to develop a diagnostic assay to predict influenza vaccine responsiveness in immunocompromised patients using identified biomarkers and machine learning models, enhancing personalized vaccination strategies.

ERC Proof of Concept
€ 150.000
2025
Details
ERC Consolid...

Molecular mimicry as a key parameter shaping T cell immunity

The MIMIC project aims to explore molecular mimicry's role in T cell recognition to enhance cancer immunotherapy by optimizing antigen selection based on pre-existing immunity insights.

ERC Consolidator Grant
€ 2.000.000
2022
Details
ERC Consolid...

Activation and switch of fates in T lymphocytes.

This project aims to model the fate choices of naïve and memory CD8+ T cells using experimental immunology and systems biology to enhance vaccine design and improve responses to infections and cancer.

ERC Consolidator Grant
€ 2.625.000
2025
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody Development

Dit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker.

Mkb-innovati...€ 153.020
2020
Details
Mkb-innovati...

From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody Development

Dit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 153.020
2020
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.